The contribution of the bone marrow (BM) immune microenvironment to acute myeloid leukemia (AML) development is well-known, but its prognostic significance is still elusive. Indoleamine 2,3-dioxygenase 1 (IDO1), which is negatively regulated by the BIN1 proto-oncogene, is an interferon-g-inducible mediator of immune tolerance. With the aim to develop a prognostic IDO1-based immune gene signature, biological and clinical data of 982 patients with newly diagnosed, nonpromyelocytic AML were retrieved from public datasets and analyzed using established computational pipelines. Targeted transcriptomic profiles of 24 diagnostic BM samples were analyzed using the NanoString's nCounter platform. BIN1 and IDO1 were inversely correlated and individually predicted overall survival. PLXNC1, a semaphorin receptor involved in inflammation and immune response, was the IDO1-interacting gene retaining the strongest prognostic value. The incorporation of PLXNC1 into the 2-gene IDO1-BIN1 score gave rise to a powerful immune gene signature predicting survival, especially in patients receiving chemotherapy. The top differentially expressed genes between IDO1(low) and IDO-1(high) and between PLXNC1(low) and PLXNC1(high) cases further improved the prognostic value of IDO1 providing a 7- and 10-gene immune signature, highly predictive of survival and correlating with AML mutational status at diagnosis. Taken together, our data indicate that IDO1 is pivotal for the construction of an immune gene signature predictive of survival in AML patients. Given the emerging role of immunotherapies for AML, our findings support the incorporation of immune biomarkers into current AML classification and prognostication algorithms.

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia / Ragaini S.; Wagner S.; Marconi G.; Parisi S.; Sartor C.; Nanni J.; Cristiano G.; Talami A.; Olivi M.; Ocadlikova D.; Ciciarello M.; Corradi G.; Ottaviani E.; Papayannidis C.; Paolini S.; Vadakekolathu J.; Cavo M.; Rutella S.; Curti A.. - In: BLOOD ADVANCES. - ISSN 2473-9537. - ELETTRONICO. - 6:1(2022), pp. 87-99. [10.1182/bloodadvances.2021004878]

An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia

Ragaini S.;Marconi G.;Sartor C.;Nanni J.;Cristiano G.;Talami A.;Ocadlikova D.;Ciciarello M.;Ottaviani E.;Papayannidis C.;
2022

Abstract

The contribution of the bone marrow (BM) immune microenvironment to acute myeloid leukemia (AML) development is well-known, but its prognostic significance is still elusive. Indoleamine 2,3-dioxygenase 1 (IDO1), which is negatively regulated by the BIN1 proto-oncogene, is an interferon-g-inducible mediator of immune tolerance. With the aim to develop a prognostic IDO1-based immune gene signature, biological and clinical data of 982 patients with newly diagnosed, nonpromyelocytic AML were retrieved from public datasets and analyzed using established computational pipelines. Targeted transcriptomic profiles of 24 diagnostic BM samples were analyzed using the NanoString's nCounter platform. BIN1 and IDO1 were inversely correlated and individually predicted overall survival. PLXNC1, a semaphorin receptor involved in inflammation and immune response, was the IDO1-interacting gene retaining the strongest prognostic value. The incorporation of PLXNC1 into the 2-gene IDO1-BIN1 score gave rise to a powerful immune gene signature predicting survival, especially in patients receiving chemotherapy. The top differentially expressed genes between IDO1(low) and IDO-1(high) and between PLXNC1(low) and PLXNC1(high) cases further improved the prognostic value of IDO1 providing a 7- and 10-gene immune signature, highly predictive of survival and correlating with AML mutational status at diagnosis. Taken together, our data indicate that IDO1 is pivotal for the construction of an immune gene signature predictive of survival in AML patients. Given the emerging role of immunotherapies for AML, our findings support the incorporation of immune biomarkers into current AML classification and prognostication algorithms.
2022
An IDO1-related immune gene signature predicts overall survival in acute myeloid leukemia / Ragaini S.; Wagner S.; Marconi G.; Parisi S.; Sartor C.; Nanni J.; Cristiano G.; Talami A.; Olivi M.; Ocadlikova D.; Ciciarello M.; Corradi G.; Ottaviani E.; Papayannidis C.; Paolini S.; Vadakekolathu J.; Cavo M.; Rutella S.; Curti A.. - In: BLOOD ADVANCES. - ISSN 2473-9537. - ELETTRONICO. - 6:1(2022), pp. 87-99. [10.1182/bloodadvances.2021004878]
Ragaini S.; Wagner S.; Marconi G.; Parisi S.; Sartor C.; Nanni J.; Cristiano G.; Talami A.; Olivi M.; Ocadlikova D.; Ciciarello M.; Corradi G.; Ottaviani E.; Papayannidis C.; Paolini S.; Vadakekolathu J.; Cavo M.; Rutella S.; Curti A.
File in questo prodotto:
File Dimensione Formato  
IDO1 score Ragaini Blood Advances.pdf

accesso aperto

Tipo: Versione (PDF) editoriale
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 1.57 MB
Formato Adobe PDF
1.57 MB Adobe PDF Visualizza/Apri
advancesADV2021004878-suppl1.pdf

accesso aperto

Tipo: File Supplementare
Licenza: Licenza per Accesso Aperto. Creative Commons Attribuzione - Non commerciale - Non opere derivate (CCBYNCND)
Dimensione 2.3 MB
Formato Adobe PDF
2.3 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11585/964269
Citazioni
  • ???jsp.display-item.citation.pmc??? 10
  • Scopus 12
  • ???jsp.display-item.citation.isi??? 10
social impact